(0.31%) 5 115.56 points
(0.31%) 38 357 points
(0.33%) 15 981 points
(-0.88%) $83.11
(5.77%) $2.03
(0.39%) $2 356.30
(0.48%) $27.67
(4.03%) $959.30
(-0.22%) $0.933
(-0.40%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology...
Stats | |
---|---|
本日の出来高 | 9 425.00 |
平均出来高 | 73 718.00 |
時価総額 | 8.38M |
EPS | £0 ( 2024-04-01 ) |
次の収益日 | ( £-3.31 ) 2024-05-15 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -0.240 |
ATR14 | £0.0710 (1.78%) |
NuCana PLC 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
NuCana PLC 財務諸表
Annual | 2023 |
収益: | £0 |
総利益: | £0 (0.00 %) |
EPS: | £-0.520 |
FY | 2023 |
収益: | £0 |
総利益: | £0 (0.00 %) |
EPS: | £-0.520 |
FY | 2022 |
収益: | £0 |
総利益: | £0 (0.00 %) |
EPS: | £-0.620 |
FY | 2021 |
収益: | £0.00 |
総利益: | £0.00 (0.00 %) |
EPS: | £-0.780 |
Financial Reports:
No articles found.
NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。